“The metabolic syndrome” is a set of metabolic abnormalities consisting of central distribution obesity, decreased concentration of cholesterol bound to high density lipoprotein (HDL), elevated triglycerides, increased blood pressure and hyperglycemia. All these disorders carry a high risk of diabetes, dyslipidemia and cardiovascular disease, and therefore an increase in mortality from these causes.
The metabolic syndrome
The relevance of this syndrome lies in its high and increasing prevalence in the vast majority of countries, to the extent that it has become one of the major public health problems, being considered by the World Health Organization (WHO) as the most important of the 21st century epidemic. The prevalence is around 24% in the general population (both men and women) and about 50% in patients with ischemic heart disease or other vascular condition.
The main objective of METASIN project is to carry out research and develop active ingredients, food and multifunctional food supplements capable of influencing the pathologies and risk factors associated with the metabolic syndrome in order to improve holistically the quality of life of this population sector.
Currently, the market for functional foods is well established in light type products, high in fiber, omega-3, probiotics for intestinal transit, or enriched with vitamins and minerals. Some of them are aimed at improving specific biomarkers considered as risk factors for certain pathological conditions. However, it not considered that many of these risk factors coexist in the metabolic syndrome.
Develop a great variety
These innovative products are designed to reduce the prevalence of the metabolic syndrome and its symptoms focusing on several biomarkers or risk factors at the same time.
The products will entail a natural alternative in the market for the treatment and / or prevention of various related diseases such as the metabolic syndrome:
Opinions of project members
Mestasin relies on good researchers that know the problem well
Mónica Olivares – Research Director
“Thanks to the application of innovative R&D, the Metasin project allows us to amplify and improve our offer of natural functional ingredients.”
Cristina Diaz – R&D Project Manager
“The Metasin project offers us the possibility to develop in a private-public collaboration framework, new innovative products that present a natural alternative for the prevention and/or treatment of various diseases related to the metabolic syndrome from a multifunctional approach..”
Pablo Gómez Rodríguez – R&D Technician
“The development of the Metasin project allows us to apply new technologies to classical emulsion systems for table sauces. We learn how to use innovative ingredients that allow us to satisfy the demand of new consumers from a health point of view but also in the search for new organoleptic sensations.”
Mercedes Villalobos – R&D Project Technician
“CARINSA will identify and obtain different active compounds that will be incorporated in food, meat and confectionary matrices with the objective to improve and/or prevent certain diseases associated with the metabolic syndrome. In addition, it will allow continuing research on the Lactobacillus plantarum probiotic (Lp3547) and determine if it can be considered as an active ingredient able to be incorporated in various matrices with effect on the metabolic syndrome.”
María Segura Fornieles – Technical Director
“The project will allow AlgaEnergy to develop various technologies for the procurement and incorporation of biomass and/or extracts coming from microalgae in an extensive number of food matrices.”
Smael Martínez – R&D Manager
“The Metasin project respresents an opportunity to improve the quality of the milk as a raw material and to develop new milk products, might it be for the final consumer or for the food industry.”
María Morillo – Research Doctor
“The collaboration of VIDA with the METASIN project will allow developing a new generation of products based on cereals that will contribute to the nutritional treatment of the metabolic syndrome. The project is completely aligned with the R&D and commercial strategy of our company.”